Elt Sight acquires MLase Ag quasi-molecular ophthalmology laser systems

November 13, 2019, ELT Sight announced that it had acquired the intellectual property and assets of MLase AG's quasi-molecular ophthalmology laser system for glauco-eye surgery, business sources said. The terms of the acquisition have not been disclosed. ELT Sight plans to expand its marketing activities in Europe in early 2020 and conduct clinical research in the United States.With offices in Munich, Germany, and Los Angeles, ELT Sight is dedicated to effective, safe and long-lasting minimally invasive glaucosis surgery. ELT Sight is a subsidiary of MLase AG, a global leader in the development and manufacture of innovative laser systems.Founded in December 2007, MLase AG is a global leader in UV healthcare, developing and producing innovative, high-quality laser and lighting systems using the latest technology. ExTra ELT, the company's innovative laser system manufactured and sold, can be used for implant-free, minimally invasive glare surgery.Glamino is the third leading cause of blindness worldwide. As the population ages, so do the number of glare sufferers. For patients, medical enterprises, and hospitals, current treatment options, including daily eye drops, invasive sifiers, stents, etc., are not ideal.Quasi-molecular laser beam incussion (ELT) is a minimally invasive glare surgery with no implants, which is precisely treated by increasing the permeability of the small beam network. Studies have shown that this method is less risky than other glare procedures, and that doctors can perform surgery within 10 minutes.The technology was first used clinically in Europe in 1997. In European studies, this outpatient surgery has shown good results and safety that can continuously reduce in-eye pressure and drug use. MLase AG's quasi-molecular ophthalmology laser system was CE certified in Europe in 2014 and is currently available in Europe.Elliott Friedman, CHIEF Executive Officer of ELT Sight, said: "The growing demand for new solutions for glaucleo is a global health challenge that is expected to affect 80 million people worldwide by 2020. Clinical studies in Europe have shown that ExTra's ELT laser system provides glare patients with a treatment that reduces eye pressure without implantation. We hope to continue to increase our marketing efforts in the European market while conducting clinical trials in the United States early next year. MrAdded: "MLase has a reputation for developing and manufacturing innovative laser systems that we hope to work with to provide the system to millions of patients worldwide affected by glare. " (Arterial mesh)